Skip to content

Clinical Study on the Mobilization of Peripheral Blood Stem Cells Using the Etoposide combined with Cyclophosphamide (EC) Regimen

Clinical Study on the Mobilization of Peripheral Blood Stem Cells Using the Etoposide combined with Cyclophosphamide (EC) Regimen

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117978
Enrollment
Unknown
Registered
2026-01-30
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma or lymphoma

Interventions

study group:EC mobilization regimen

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. 18 <= Age <= 70 years old, gender not limited; 2. Lymphoma and multiple myeloma with indications for autologous stem cell transplantation; 3. ECOG Physical Fitness Status Score <= 2 points; 4. No serious complications, such as liver failure, kidney failure, or heart failure; 5. sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Previously received hematopoietic stem cell transplantation; 2. History of failed stem cell collection in the past; 3. Severe uncontrolled infection; 4. Patients with severe organ dysfunction; 5. Allergic to cyclophosphamide or etoposide; 6. Received pelvic radiotherapy; 7. Pregnant or lactating women; 8. Researchers believe that there are other situations that are not suitable for participating in this experiment.

Design outcomes

Primary

MeasureTime frame
Successful mobilization rate;

Secondary

MeasureTime frame
Number of CD34 + cells collected;Excellent mobilization rate;side effect;Number of collections;

Countries

China

Contacts

Public ContactHongyan Tong

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

hongyantong@aliyun.com+86 571 87236625

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026